Artificial Intelligence for Multiple Long-term conditions (AIM): A consensus statement from the NIHR AIM consortia
Strategy Document
Artificial Intelligence for Multiple Long-term conditions (AIM): A consensus statement from the NIHR AIM consortia
[version 1; not peer reviewed]Sarah Finer is the Deputy Lead of Genes & Health, a large research programme which receives support from multiple UKRI funders and and a Life Sciences partnership including Astra Zeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline Research and Development Limited, Maze Therapeutics Inc, Merck Sharp & Dohme LLC, Novo Nordisk A/S, Pfizer Inc, Takeda Development Centre Americas Inc. Iain Buchan is Chief Data Scientist Advisor for AstraZeneca. Simon Fraser, as well as being a Public Health academic, works part time for the NIHR Evaluations Trials and Studies Coordinating Centre (NETSCC) as a Consultant in Public Health/Consultant Advisor.
All commenters must hold a formal affiliation as per our Policies. The information that you give us will be displayed next to your comment.
User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the User Comment Terms and Conditions. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.
Use of this website is subject to the NIHR Open Research General Terms and Conditions.
Submission of user comments to this website is subject to additional Terms and Conditions. By clicking “I accept the User Comment Terms and Conditions” before you submit your first comment, you agree to be bound by these conditions every time you submit a comment.
Terms relating to user comments